Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Acute ketone supplementation in the absence of muscle glycogen utilization: Insights from McArdle disease

    Clinical Nutrition, Vol. 43, Núm. 3, pp. 692-700

  2. Dose–response effect of pre-exercise carbohydrates under muscle glycogen unavailability: Insights from McArdle disease

    Journal of Sport and Health Science, Vol. 13, Núm. 3, pp. 398-408

  3. Exercise Intolerance in McArdle Disease: A Role for Cardiac Impairment? A Preliminary Study in Humans and Mice

    Medicine and Science in Sports and Exercise

2023

  1. Muscle glycogen unavailability and fat oxidation rate during exercise: Insights from McArdle disease

    Journal of Physiology, Vol. 601, Núm. 3, pp. 551-566

2022

  1. Long-Term Exercise Intervention in Patients with McArdle Disease: Clinical and Aerobic Fitness Benefits

    Medicine and science in sports and exercise, Vol. 54, Núm. 8, pp. 1231-1241

  2. Low aerobic capacity in McArdle disease: A role for mitochondrial network impairment?

    Molecular metabolism, Vol. 66, pp. 101648

2021

  1. The Second Wind in McArdle Patients: Fitness Matters

    Frontiers in Physiology, Vol. 12

2008

  1. Efectividad y tolerabilidad del ácido zoledrónico en el tratamiento del cancer de próstata metastásico

    Actas Urologicas Espanolas, Vol. 32, Núm. 5, pp. 492-501

2000

  1. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3095 Spanish patients evaluated during general practice

    European Urology, Vol. 37, Núm. 4, pp. 421-427

  2. The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

    BJU International, Vol. 86, Núm. 4, pp. 432-438